FDA
The new article provides further clarification on the regulatory policy, emphasizing the key aspects to be considered in order to ensure compliance with the relevant regulatory requirements.
FDA
The new article refers to additional resources to be taken into consideration by the parties involved in operations with laboratory-developed tests.
BfArM
The article outlines the key points related to reporting serious adverse events in the context of clinical trials.
FDA
The final article dedicated to Diversity Action Plans describes certain specific aspects pertaining to the matter, emphasizing the key considerations.
FDA
The new article is dedicated to enrollment goals, highlighting the aspects related to the rationale behind them and the way they should be measured.
FDA
The new article pays special attention to the content of Diversity Action Plans, emphasizing the aspects related to the relevant goals.
